ClearPoint Neuro, Inc.
NASDAQ:CLPTMedical - Devices
+$0.89 today
- Market cap
- $247.14M
- Beta
- 1.31
- P/E (TTM)
- -18.0
- EPS (TTM)
- -$0.98
Volume 0.64M
Average 0.67M
CLPT Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
ClearPoint Neuro, Inc.NASDAQ: CLPT
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation grows in line with its trailing trend
Q1 FY2026 stock-based compensation of $2.22M rose 16.2% year over year, in line with the +16.1% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 12.0% from the prior quarter. Over 3 fiscal years it compounded at +25.6% a year.
Context
- Stock-based compensation amounted to 22.1% of revenue in FY2025, up 0.1 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +16.2% holds above the trailing-twelve-month pace of +16.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 8.18M USD
- Year-over-year change
- +18.4%
- 4-year CAGR
- +40.9%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.18M | +18.4% |
| FY2024 | 2024-12-31 | 6.91M | +13.6% |
| FY2023 | 2023-12-31 | 6.08M | +47.3% |
| FY2022 | 2022-12-31 | 4.13M | +98.6% |
| FY2021 | 2021-12-31 | 2.08M | — |
Stock-Based Compensation vs competitors
How CLPT compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +16.1% is the 3rd highest of 10, against a peer median of -10.7%.
- Stock-based compensation amounts to 20.9% of revenue for CLPT, versus a peer median of 5.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $42.3M USD | +40.4% | +15.9% | 5.1% | |
| LTM Mar 2026 | $27.48M USD | -5.7% | +25.8% | 31.9% | |
| LTM Mar 2026 | $24.89M USD | -2.4% | +3.4% | 12.1% | |
| LTM Mar 2026 | $22.82M USD | -18.0% | +14.0% | 11.2% | |
| LTM Mar 2026 | CA$13.13M CAD | -20.8% | +12.9% | 1.4% | |
| LTM Mar 2026 | $12.76M USD | +67.9% | -14.2% | 5.5% | |
| LTM Mar 2026 | $12.55M USD | -31.5% | +1.2% | — | |
| LTM Mar 2026 | $12.5M USD | -10.7% | -7.5% | 1.7% | |
| LTM Apr 2026 | $10.9M USD | -28.8% | +2.3% | 1.3% | |
| LTM Mar 2026 | $8.49M USD | +16.1% | +25.6% | 20.9% | |
| Peer median (excluding CLPT) | — | -10.7% | +3.4% | 5.3% | |
Competitors are the stored peer set for CLPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (14.41M) | (16.43M) | (22.09M) | (18.91M) | (25.54M) |
| Depreciation & Amortization | 692K | 777K | 1.51M | 1.9M | 982K |
| Deferred Income Tax | 202K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.08M | 4.13M | 6.08M | 6.91M | 8.18M |
| Change in Working Capital | (1.68M) | (4.29M) | (1.4M) | 1.4M | (9.81M) |
| Accounts Receivables | 627K | (211K) | (1.8M) | (1.21M) | (268K) |
| Inventory | (1.71M) | (4.42M) | 1.25M | 743K | (103K) |
| Accounts Payables | (762K) | 1.59M | 0 | 3.11M | (7.52M) |
| Other Working Capital | 165K | (1.25M) | (846K) | (1.24M) | (1.92M) |
| Other Non-Cash Items | 425K | 3.78M | 2.18M | (245K) | 2.27M |
| Operating Cash Flow | (12.7M) | (16.17M) | (13.72M) | (8.95M) | (23.93M) |
| Capital Expenditures | (168K) | (253K) | (717K) | (275K) | (522K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 1.14M |
| Purchases of Investments | 0 | (21.59M) | 0 | 0 | 0 |
| Sales of Investments | 0 | 12M | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 9.67M | 0 | 0 |
| Investing Cash Flow | (168K) | (10.74M) | 8.95M | (275K) | 615K |
| Debt Repayment | 0 | 0 | 0 | (10M) | 48.09M |
| Common Stock Issued | 46.79M | 745K | 0 | 16.15M | 3.95M |
| Common Stock Repurchased | 0 | 0 | (210K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 90K | (336K) | 506K | 40K | (1.86M) |
| Financing Cash Flow | 46.88M | 409K | 296K | 6.19M | 50.18M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 34.01M | (26.49M) | (4.48M) | (3.04M) | 26.87M |
| Free Cash Flow | (12.87M) | (16.42M) | (14.44M) | (9.23M) | (24.45M) |
ClearPoint Neuro, Inc.
NASDAQ:CLPT
Intrinsic Alpha fair value
Locked
Current Price
$7.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.